These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33621992)

  • 1. [Apalutamide in patients with high-risk M0CRPC: data from the pivotal SPARTAN study and initial experience from a compassionate use program].
    Hellmis E; Schwentner C; Mandel P; Banek S; Gleißner J; Bögemann M
    Aktuelle Urol; 2023 Apr; 54(2):140-147. PubMed ID: 33621992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program].
    Spiegelhalder P; Bögemann M
    Aktuelle Urol; 2022 Feb; 53(1):60-63. PubMed ID: 33882583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Dearden L; Capone C; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2022 Jan; 39(1):518-531. PubMed ID: 34797506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
    Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.
    Alpajaro SIR; Harris JAK; Evans CP
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):16-23. PubMed ID: 30115959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
    Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
    Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
    Hegele A; Häußermann R; Schultheis S; Skrobek L; Vink M; Hollwegs S; Ludwig M; Huwe P; Maywurm M; Bartsch-Polle A; Weber J; Thiemer M; Varughese D
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):414. PubMed ID: 39249593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of nonmetastatic CRPC : Androgen receptor inhibition as new treatment standard in nonmetastatic castration-resistant prostate cancer with high risk of metastasis].
    Hadaschik B; Hellmis E
    Urologe A; 2021 Jun; 60(6):753-759. PubMed ID: 33575824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
    Small EJ; Chi KN; Chowdhury S; Bevans KB; Bhaumik A; Saad F; Chung BH; Karsh LI; Oudard S; De Porre P; Brookman-May SD; McCarthy SA; Mundle SD; Uemura H; Smith MR; Agarwal N
    Eur Urol Oncol; 2024 Aug; 7(4):844-852. PubMed ID: 38072759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer.
    Swami U; Agarwal N
    Cancer Treat Res Commun; 2020; 25():100205. PubMed ID: 32822968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy.
    Oudard S; Hadaschik B; Saad F; Cella D; Basch E; Graff JN; Uemura H; Dibaj S; Li S; Brookman-May SD; De Porre P; Bevans KB; Trudeau JJ; Small EJ; Smith MR
    Eur Urol Focus; 2022 Jul; 8(4):958-967. PubMed ID: 34479838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Tilki D; Graefen M; Kluth LA; Briganti A; Mandel P; Montorsi F; Chun FKH; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):139-148. PubMed ID: 34054128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.
    Mori K; Mostafaei H; Pradere B; Motlagh RS; Quhal F; Laukhtina E; Schuettfort VM; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    Int J Clin Oncol; 2020 Nov; 25(11):1892-1900. PubMed ID: 32924096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
    Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
    Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice.
    Bögemann M; Facchini G; Bauernhofer T; Cathomas R; Xylinas E; Tombal B
    Ir J Med Sci; 2023 Dec; 192(6):2643-2651. PubMed ID: 36944842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.
    Feng FY; Thomas S; Saad F; Gormley M; Yu MK; Ricci DS; Rooney B; Brookman-May S; McCarthy S; Olmos D; Chowdhury S; Hadaschik B; Liu Y; Davicioni E; Smith MR; Small EJ
    JAMA Oncol; 2021 Jul; 7(7):1005-1014. PubMed ID: 34081076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M0CRPC overview of management options.
    Hess-Busch Y; Hadaschik B; Hess J
    World J Urol; 2021 Feb; 39(2):349-356. PubMed ID: 31691081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.